HLB bioStep Decides Early Acquisition of 9.75 Billion Won in Convertible Bonds, Eliminating 6.54% Potential Dilution and Improving Capital Structure
HLB bioStep decided on July 14, 2026 through a board resolution to early acquire 9.75 billion won of its 4th unregistered private convertible bonds totaling 20 billion won before maturity.
The acquisition amount is 10.039 billion won including principal and interest, funded by internal cash reserves via over-the-counter purchase.
This acquisition reduces the remaining convertible bond balance to 10 billion won and eliminates potential dilution of 1.22 million shares equivalent to 6.54% of outstanding shares.
The conversion price of the remaining bonds is 7,990 won, significantly higher than the current stock price of 1,933 won, lowering conversion incentives but retaining residual risk.
Among sellers, HLB Life Science a related party to the largest shareholder sold 2 billion won worth, and HLB Life Science reported a net loss of 99.9 billion won in 2025 indicating weak financial health.
[AI Summary]HLB bioStep early acquisition of convertible bonds alleviates dilution concerns but uses 10 billion won of internal cash reducing financial flexibility. The remaining 10 billion won bonds with high conversion price pose limited immediate dilution risk, though monitoring of cash flow and related company financials is warranted.
KOSDAQ Filing Information
Report On Major Events (Decision On Acquisition Before Maturity Of Self-Convertible Bonds)